Evasion of Influenza A Viruses from Innate and Adaptive Immune Responses

por van de Sandt, Carolien E., Kreijtz, Joost H. C. M., Rimmelzwaan, Guus F.
Publicado 2012

Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis

por Ramezanpour, Bahar, Pronker, Esther S., Kreijtz, Joost H.C.M., Osterhaus, Albert D.M.E., Claassen, E.
Publicado 2015

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

por Altenburg, Arwen F., Kreijtz, Joost H. C. M., de Vries, Rory D., Song, Fei, Fux, Robert, Rimmelzwaan, Guus F., Sutter, Gerd, Volz, Asisa
Publicado 2014

Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine

por de Vries, Rory D., De Gruyter, Heidi L.M., Bestebroer, Theo M., Pronk, Mark, Fouchier, Ron A.M., Osterhaus, Albert D.M.E., Sutter, Gerd, Kreijtz, Joost H.C.M., Rimmelzwaan, Guus F.
Publicado 2015

Vaccination against Human Influenza A/H3N2 Virus Prevents the Induction of Heterosubtypic Immunity against Lethal Infection with Avian Influenza A/H5N1 Virus

por Bodewes, Rogier, Kreijtz, Joost H. C. M., Baas, Chantal, Geelhoed-Mieras, Martina M., de Mutsert, Gerrie, van Amerongen, Geert, van den Brand, Judith M. A., Fouchier, Ron A. M., Osterhaus, Albert D. M. E., Rimmelzwaan, Guus F.
Publicado 2009

MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization

por Kreijtz, Joost H. C. M., Suezer, Yasemin, de Mutsert, Gerrie, van Amerongen, Geert, Schwantes, Astrid, van den Brand, Judith M. A., Fouchier, Ron A. M., Löwer, Johannes, Osterhaus, Albert D. M. E., Sutter, Gerd, Rimmelzwaan, Guus F.
Publicado 2009